{"nct_id":"NCT03924895","title":"Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-08","start_date":"2019-07-24","start_date_type":"ACTUAL","primary_completion_date":"2025-06-06","primary_completion_date_type":"ACTUAL","completion_date":"2027-12-15","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}